A J de Langen - Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 23 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial

B. C. Cho,D. R. Camidge, J. J. Lin,S. -W. Kim,B. Solomon, R. Dziadziuszko, B. Besse,K. Goto,A. J. de Langen,J. Wolf, K. H. Lee, S. Popat,

JOURNAL OF THORACIC ONCOLOGY（2023）

引用0浏览0引用

Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02

P. Janne, Y. Goto, T. Kubo, K. Ninomiya,S. -W. Kim, D. Planchard, M. -J. Ahn, E. F. Smit,A. J. de Langen, M. Perol, E. Pons-Tostivint,S. Novello,

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S148-S148

引用0浏览0引用

PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1

B. Sherif, B. Besse, B. Solomon, L. Bazhenova,D.W. Kim, J.J. Lin, J. Wolf, S. Popat, K. Goto,A.J. de Langen, C. Springfeld, M. Reynolds,

Value in Healthno. 12 (2023): S484

引用0浏览0引用

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

M Jebbink,A J de Langen,K Monkhorst, M C Boelens,D van den Broek,V van der Noort,C J de Gooijer, M Mahn,A J van der Wekken,L Hendriks, S M S Hashemi,M S Paats,

JTO clinical and research reportsno. 4 (2023): 100481-100481

引用1浏览0WOS引用

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer

J M van Berge Henegouwen, M Jebbink, L R Hoes,H van der Wijngaart, L J Zeverijn,D L van der Velden, P Roepman,W W J de Leng,A M L Jansen,E van Werkhoven,V van der Noort,A J van der Wekken,

European Journal of Cancer（2022）

引用4浏览0WOS引用

Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

M. L. Johnson,A. J. de langen,D. M. Waterhouse,J. Mazieres,A-M. C. Dingemans,G. Mountzios,M. Pless,J. Wolf,M. Schuler,H. Lena, F. Skoulidis,I. Okamoto,

ANNALS OF ONCOLOGY（2022）

引用24浏览0引用

RCT of first-line TKI versus intercalated TKI with chemotherapy for EGFR mutated NSCLC

Rolof G. P. Gijtenbeek,Vincent van der Noort,Joachim G. J. V. Aerts, Jeske A. Staal – van den Brekel,Egbert F. Smit,Frans H. Krouwels,Frank A. Wilschut,T. Jeroen N. Hiltermann,Wim Timens,Ed Schuuring,Joost D. J. Janssen,Martijn Goosens,

ERJ Open Researchpp.00239-2022, (2022)

引用3浏览0引用

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

Rolof G P Gijtenbeek,Vincent van der Noort,Joachim G J V Aerts, Jeske A Staal-van den Brekel,Egbert F Smit,Frans H Krouwels,Frank A Wilschut,T Jeroen N Hiltermann,Wim Timens,Ed Schuuring,Joost D J Janssen,Martijn Goosens,

ERJ OPEN RESEARCH（2022）

引用3浏览0WOS引用

Phase 2 Study Of Zenocutuzumab (Mcla-128), A Bispecific Her2/Her3 Antibody In Nrg1 Fusion-Positive Advanced Solid Tumors

A. Schram, T. Macarulla, E. O'Reilly, J. Rodon, B. Wolpin,S. Ou,D. Kim,J. C. Yang,J. Lam,A. De Langen, V. Boni,G. Cerea,

JOURNAL OF THORACIC ONCOLOGY（2021）

引用2浏览0引用

Orchard: A Biomarker-Directed Phase 2 Platform Study In Pts With Advanced Egfrm Nsclc Progressing On First-Line Osimertinib

B. C. Cho,Z. Piotrowska,X. Le,S. B. Goldberg,J. Goldman,A. De Langen,I. Okamoto,P. Smith,I. Mensi,J. Maidment,R. Hartmaier,M. Li,

JOURNAL OF THORACIC ONCOLOGY（2021）

引用4浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn